Xiaomeng Liu

Xiaomeng Liu

Auto-generated profile, based on publicly available information

Xiaomeng Liu

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
CLChengxin Liu
Chengxin Liu
YDYang Du
Yang Du
DHDan Han
Dan Han
BLBaosheng Li
Baosheng Li
XLXiaomeng Liu
Xiaomeng Liu
WHWei Huang
Wei Huang
Patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. In this single-arm, phase II study, eligible patients received two cycles of induction serplulimab plus chemotherapy. Patients without progression underwent multidisciplinary restaging to receive either cCRT with serplulimab consolidation or surgery. The primary endpoints were objective response rate (ORR) after cCRT and changes in lung volume receiving ≥20 Gy (V20). Forty-nine patients were enrolled (75.5% stage IIIB/IIIC). Following induction, the V20 value was significantly reduced by 11.41% (P < 0.001). The ORR following cCRT was 77.14% (95% confidence interval, 59.86%–89.58%). The 12-month progression-free survival and overall survival rates were 76.15% and 90.54%, respectively. Notably, six patients successfully underwent R0 resection, with five achieving a pathologic complete response. Grade 3 adverse events occurred in 14.29% of patients, and toxicities were manageable. Induction serplulimab–chemotherapy prior to cCRT is a promising strategy for bulky, stage III NSCLC. This approach significantly reduced radiation volumes, achieved high response rates, and enabled curative surgery in selected patients with manageable toxicity.

2 June 2026
Verified
Other
Open access
CLChengxin Liu
Chengxin Liu
YDYang Du
Yang Du
DHDan Han
Dan Han
BLBaosheng Li
Baosheng Li
XLXiaomeng Liu
Xiaomeng Liu
WHWei Huang
Wei Huang
Supplementary Figure 3. Longitudinal dynamics of peripheral blood lymphocytes.

2 June 2026
Verified
Other
Open access
CLChengxin Liu
Chengxin Liu
YDYang Du
Yang Du
DHDan Han
Dan Han
BLBaosheng Li
Baosheng Li
XLXiaomeng Liu
Xiaomeng Liu
WHWei Huang
Wei Huang
Patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC) face poor outcomes with standard concurrent chemoradiotherapy (cCRT) due to large radiation fields and toxicity risks. We evaluated the feasibility and efficacy of induction immunochemotherapy to downstage tumors prior to cCRT. In this single-arm, phase II study, eligible patients received two cycles of induction serplulimab plus chemotherapy. Patients without progression underwent multidisciplinary restaging to receive either cCRT with serplulimab consolidation or surgery. The primary endpoints were objective response rate (ORR) after cCRT and changes in lung volume receiving ≥20 Gy (V20). Forty-nine patients were enrolled (75.5% stage IIIB/IIIC). Following induction, the V20 value was significantly reduced by 11.41% (P < 0.001). The ORR following cCRT was 77.14% (95% confidence interval, 59.86%–89.58%). The 12-month progression-free survival and overall survival rates were 76.15% and 90.54%, respectively. Notably, six patients successfully underwent R0 resection, with five achieving a pathologic complete response. Grade 3 adverse events occurred in 14.29% of patients, and toxicities were manageable. Induction serplulimab–chemotherapy prior to cCRT is a promising strategy for bulky, stage III NSCLC. This approach significantly reduced radiation volumes, achieved high response rates, and enabled curative surgery in selected patients with manageable toxicity.

2 June 2026
Verified
Other
Open access
CLChengxin Liu
Chengxin Liu
YDYang Du
Yang Du
DHDan Han
Dan Han
BLBaosheng Li
Baosheng Li
XLXiaomeng Liu
Xiaomeng Liu
WHWei Huang
Wei Huang
Supplementary Figure 2. Sensitivity analysis of survival outcomes.

2 June 2026
Verified
Other
Open access
PDF file
CLChengxin Liu
Chengxin Liu
YDYang Du
Yang Du
DHDan Han
Dan Han
BLBaosheng Li
Baosheng Li
XLXiaomeng Liu
Xiaomeng Liu
WHWei Huang
Wei Huang
Supplementary Figure 1. Subgroup analysis of progression-free survival (PFS).